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Neuromyotonia: Potassium channelopathy  
or non ionic disease?
G. Serratrice
CHU La Timone, Marseille, France
The  early  pathophysiologic  study  showed  increasing  evi-
dence that autoimmunity is implicated in the pathogenesis of neu-
romyotonia. Antibodies to voltage gated potassium channel were 
detected in the serum of patients who had peripherical nerves hy-
perexcitability and also Morvan’s disease or limbic encephalitis. 
These discoveries offered new approaches to treatments.
Recently, antibodies previously attributed to VGKC rec-
ognise 2 surface antigens LGI1 and CASPR2 into the VGKC 
complex. Finally, VGKC antibodies are directed to 2 proteins 
the first one is a key hippocampic protein containing pre and 
post synaptic proteins. The second one CASPR2 is an hippoc-
ampic and paranodal protein. There clinical significance is dif-
ferent: hyperexcitability limbic encephalitis without thymoma 
for LGI1, hyperexcitability Morvan limbic encephalitis and fre-
quent thymoma for CASPR2.
In  conclusion,  the  term  NMT  -  LE  - VGKC  should  be 
changed to NMT- LE with LGI1 and CASPR2 antibodies and 
classified as auto immune synaptic disorders.
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Crossing barriers: how medical doctors and 
researchers can partner with Advocacy Groups
L. Feld
Periodic Paralysis Association Vice President, Orlando, Florida, USA
Disease advocacy groups (DAGs) by and large arise in chron-
ic or devastating diseases for which persistent unmet needs exist. 
Patients seek DAGs for a variety of reasons, but most importantly 
to find immediate psychological, diagnostic, and therapeutic cop-
ing mechanisms. Factors that drive their continued involvement 
include hope for finding a permanent cure and an altruistic desire 
to increase awareness and share their experiences to help others 
in similar need. In doing so, they frequently establish a conduit 
to world experts in their rare disorder, and where needed, better 
define disease characteristics and management.
DAGs provide help to their members in a variety of ways:
1)  offer web-based, easily accessible and medically reliable 
information to patients about their condition;
2)  offer a means of members to interact either through email 
list serves, blogs, or message boards;
3)  organize annual meetings for members, whereby disease 
experts and members can interact face to face;
4)  offer a virtual interface between medical experts and their 
membership via on-line “Ask The Experts”;
5)  potentiate blood banking and genetic research by gathering 
relatively large numbers of patients in one repository;
6)  organize and galvanize scientific and medical experts to re-
search the condition;
7)  motivate experts to help the DAG members.
Physicians  are  the  ultimate  backbone  of  any  DAG  that 
wishes to provide more than psychosocial coping modalities 
for  their  members.  Members  ultimately  seek  credible  medi-
cal knowledge as the best chance to navigate their illness and 
achieve normalcy in their lives. The fundamental ways in which 
physicians can support a DAG is by being actively available to 
attend DAG member conferences, answer member questions, 
contribute to website content, and cooperate to establish con-
sensus protocols for diagnosis and therapy, and work with each 
other to find meaningful diagnostic modalities and treatments.
Barriers to a DAG’s achieving its mission are many. DAGs 
often lack funding, frequently suffer from disinterest by a majority 
of the few medical experts interested in their disease, are some-
times hurt by splinter groups for the same disease fragmenting 
limited resources, and may find themselves caught between politi-
cal or personality differences among their medical experts.
Barriers  to  physician  participation  in  DAGs  are  many: 
competition for time of the physician by other diseases, lim-
ited time to deal with individual patient concerns, medico-legal 
uncertainties of interactions with DAG members, lack of rec-
ognition or peer reviewed publication credit for writing web-
site content, cost of travel to meetings, having only non-clinical 
research interest, and knowledge in only a limited aspect of a 
disease in question.
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Functional evaluation of muscle impairment  
in neuromuscular disorders
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in Myotonic Dystrophy
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Current therapeutic guidelines in Duchenne 
Muscular Dystrophy to prolong life
V. Riccio, I. Riccio, F. Gimigliano, D. Riccardi, G. Riccardi, 
R. Gimigliano, L. Politano1, G. Nigro1, G. Duport1, Y. Rideau1
Dipartimento di Scienze Ortopediche, Traumatologiche, Riabilitative e 
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Duchenne’s myopathy is an X-linked disease with well de-
fined evolutionary phases, characterized by degradation of the 157
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walking function, development of evolutive scoliosis and pro-
gressive decline of the respiratory function leading patients to 
premature death.
In 1985 Y. Rideau in France carried out a new global thera-
peutic strategy for treatment of lower limb deformities, scoliosis 
deformity and progressive restrictive syndrome.
The indication for surgery at the lower limbs is made very 
early, at the onset of the first signs of disease. The procedures 
are carried out at the same time and always bilaterally; they in-
clude: (i) hip section of superficial flexors; (ii) iliotibial band 
resection; (iii) subcutaneous tenotomy of semitendineous and 
gracilis; (iv) subcutaneous lengthening of Achilles tendons.
In the post-operative period, the patient begins exercises of 
active and passive mobility in few days and after three weeks re-
covers his performances; ambulation will remain almost normal 
for several years. A comparison of two groups of patients, the 
first precociously operated on the lower limbs, the other one not 
operated, shows better performances in the operated group.
The indications for surgical treatment of Duchenne scolio-
sis must be made after the loss of ambulation and not too late, to 
avoid the concurrent respiratory restrictive syndrome makes the 
patient inoperable. Over ten years ago, in Poitiers, a specific in-
strumentation for Duchenne scoliosis was created, providing for 
cylindrical rods fixed by peduncular screws at the sacro-lumbar 
level. On the dorso-lumbar level, the rod becomes flat to allow 
more flexibility of the trunk. The complications observed in a 
group of 55 patients operated for scoliosis, consisted in 2 cases 
of breaking of rods and 1 superficial infection. The surgery ap-
proach in DMD has the double aim to prolong the time of the 
autonomous ambulation and to avoid the evolution of scoliosis, 
limiting the harmful effects of the scoliosis on the respiratory 
function.
However, the surgery alone is unable to prolong the life 
expectancy in these patients, without treating the restrictive res-
piratory syndrome, first by nasal ventilation and then by elective 
tracheotomy, essential for the survival of the patient.
I-22
Early indicators of respiratory impairment  
in muscular dystrophies: from bioengineering 
to rehabilitation
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Respiratory rehabilitation in Duchenne 
Muscular Dystrophy
G. Fiorentino, A. Annunziata, R. Cauteruccio, M. Caputi
Cardiorespiratory Department, Monaldi Hospital, Second University of 
Naples, Italy
Lung function in Duchenne Muscular Dystrophy (DMD) is 
complicated by a decline in vital capacity (VC). After an initial 
period of normal increase in VC, that typically reach a plateau 
between 12 and 16 years, there is a period of decline, estimated 
in  200ml/year.  The  deterioration  of  the  respiratory  function 
(restrictive syndrome) is one of the two major causes of death 
in these patients and a close correlation between the develop-
ment of respiratory symptoms and VC has been observed. An 
indirect consequence of intercostals muscles (IM) weakness is 
a reduction in respiratory system compliance (RSC), the ratio 
of the change inspiratory system volume to a change in pres-
sure (RSC = AV/AP). Mobilisation of secretions, by postural 
drainage, is an important step in the clinical pathway of airway 
clearance and of vital importance in DMD. Therapy should be 
provided for no longer than necessary to obtain the desired ther-
apeutic results. The use of airway clearance techniques, includ-
ing assisted coughing techniques, both manual and mechanical, 
is strongly recommended. These techniques should always be 
included in the treatment of chronic NMD patients. Cough can 
be assisted by manual and mechanical means. All methods re-
quire a combination of improved insufflation of the lungs to 
achieve sufficient lung volumes for an effective cough in con-
junction with adequate forced expiratory techniques to increase 
the patient’s natural, but weakened, cough. Glossopharyngeal 
breathing (GPB) is the act of the glottis taking air and propel-
ling it into the lungs. Some authors affirm that GPB can sustain 
normal ventilation throughout daytime hours without using a 
ventilator, and safely in the event of ventilator failure during 
sleep in patients with reduced inspiratory muscle function. In 
our opinion there is not enough evidence for generalised use of 
GPB alone to avoid invasive ventilatory assistance.
The cough assist machine (the mechanical insufflator-ex-
sufflator) has proven to be useful to airway clearance in patients 
with  neuromuscular  weakness.  It  provides  both  an  inspira-
tory phase (to inflate the lungs) and an expiratory phase (for 
the actual cough), all in one piece of equipment. Studies have 
shown that the Cough-Assist machine is well tolerated, without 
increased risk for complications such as pneumo-thorax, gas-
tro-esophageal reflux, or pulmonary hemorrhage. It also can be 
used through various interfaces such as mouth, full face mask, 
or endotracheal or tracheostomy tube.
The indications for tracheostomy include: 1) NIPPV no 
longer effective at treating hypoventilation; 2) NIPPV not toler-
ated by the patient; 3) Excessive oral secretions; 4) Resources 
for outpatient management with NIPPV not available in the 
community; 5) Failure to extubate patient who has been intu-
bated for whatever reason. In our experience tracheostomy is 
performed in election, when the vital capacity is about 700-
1000 ml, so that the patient can long remain without constant 
ventilatory support.